Respiratory effects of oral mitragynine and oxycodone in a rodent model. Compare the respiratory effects of oral mitragynine to oral oxycodone in rats for evaluating effects of opioids Consistent with mitragynine’s pharmacology that includes partial µ-opioid receptor agonism with little recruitment of the respiratory depressant activating β-arrestin pathway, mitragynine produced no evidence of respiratory depression at doses many times higher than known to be taken by humans. #Kratom #Mitragynine #Oxycodone #Safety #Respiratorydepression #Rat #Animalmodel #Pharmacokinetics #Pharmacodynamics #Opioidepidemic #research #study https://kratomlords.com/kratom-research/respiratory-effects-mitragynine-oxycodone/

atai Life Sciences - Phase 1 trial of kratom-derived pharmaceutical atai and Kures are poised to address two key factors underlying the opioid epidemic developing a potentially safer and more widely available alternative for both pain management and opioid maintenance therapy. One of the leading therapeutic indicators of kratom is its analgesic effect. One study of Kratom users in Malaysia showed that 90% were using kratom as a substitute for opioids, with 84% reporting that kratom eased their opioid withdrawal symptoms. #7hydroxymitragynine #atai #kratom #KratomEffects #opioids #alternative #KratomResearch #KratomStudy #kratomtrial #mitragynaspeciosa #pharmaceutical #WhatisKratom https://kratomlords.com/kratom-research/atai-life-sciences-phase-1-trial-kratom-derived-pharmaceutical/